R F Wang

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
    R F Wang
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 161:3598-606. 1998
  2. ncbi request reprint Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen
    R F Wang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Science 284:1351-4. 1999
  3. ncbi request reprint Human tumor antigens: implications for cancer vaccine development
    R F Wang
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Mol Med (Berl) 77:640-55. 1999
  4. ncbi request reprint Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens
    R F Wang
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892 1502, USA
    Cancer Res 58:3519-25. 1998
  5. ncbi request reprint Human tumor antigens for cancer vaccine development
    R F Wang
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA
    Immunol Rev 170:85-100. 1999
  6. ncbi request reprint Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33
    R F Wang
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 160:890-7. 1998
  7. pmc CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production
    G Zeng
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:3964-9. 2001
  8. pmc Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
    R F Wang
    National Cancer Institute, Bethesda, Maryland 20892, USA
    J Exp Med 184:2207-16. 1996
  9. pmc Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells
    R F Wang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Exp Med 189:1659-68. 1999
  10. ncbi request reprint The use of melanosomal proteins in the immunotherapy of melanoma
    Y Kawakami
    Surgery Branch, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Immunother 21:237-46. 1998

Collaborators

Detail Information

Publications14

  1. ncbi request reprint A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
    R F Wang
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 161:3598-606. 1998
    ..Understanding of this mechanism by which the alternative reading frame is translated may have important implications in tumor immunology...
  2. ncbi request reprint Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen
    R F Wang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Science 284:1351-4. 1999
    ....
  3. ncbi request reprint Human tumor antigens: implications for cancer vaccine development
    R F Wang
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Mol Med (Berl) 77:640-55. 1999
    ..This review summarizes the current status of tumor antigens and their potential applications to cancer treatment...
  4. ncbi request reprint Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens
    R F Wang
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892 1502, USA
    Cancer Res 58:3519-25. 1998
    ....
  5. ncbi request reprint Human tumor antigens for cancer vaccine development
    R F Wang
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA
    Immunol Rev 170:85-100. 1999
    ..This review will summarize the current status of MHC class I- and class II-restricted human tumor antigens, and their potential application to cancer treatment...
  6. ncbi request reprint Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33
    R F Wang
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 160:890-7. 1998
    ..However, peptide titration experiments showed that the affinity of TCR receptor to peptide/A33 could be higher than that to the peptide/A31. These studies have important implications for the development of peptide-based cancer vaccines...
  7. pmc CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production
    G Zeng
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:3964-9. 2001
    ....
  8. pmc Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
    R F Wang
    National Cancer Institute, Bethesda, Maryland 20892, USA
    J Exp Med 184:2207-16. 1996
    ..Like other melamona differentiation antigens, TRP-2 was only expressed in melanoma, melanocytes, and retina, but not in other human tissues tested...
  9. pmc Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells
    R F Wang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Exp Med 189:1659-68. 1999
    ..This represents the first demonstration that a fusion protein resulting from a chromosomal rearrangement in tumor cells serves as an immune target recognized by CD4(+) T cells...
  10. ncbi request reprint The use of melanosomal proteins in the immunotherapy of melanoma
    Y Kawakami
    Surgery Branch, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Immunother 21:237-46. 1998
    ..These studies may demonstrate the feasibility of using melanosomal proteins for the immunotherapy of patients with melanoma...
  11. pmc Tumor antigens discovery: perspectives for cancer therapy
    R F Wang
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20814, USA
    Mol Med 3:716-31. 1997
    ..This review will summarize the current status and progress toward identifying human tumor antigens and their potential applications to cancer treatment...
  12. pmc Immunization against endogenous retroviral tumor-associated antigens
    M H Kershaw
    Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 61:7920-4. 2001
    ..The ability to immunize against endogenous retroviral tumor antigens may have relevance in the induction of antitumor immunity for some human cancers...
  13. pmc Escherichia coli mrsC is an allele of hflB, encoding a membrane-associated ATPase and protease that is required for mRNA decay
    R F Wang
    Department of Genetics, University of Georgia, Athens 30602 7223, USA
    J Bacteriol 180:1929-38. 1998
    ..The data presented provide the first direct evidence for the involvement of a membrane-bound protein in mRNA decay in E. coli...
  14. ncbi request reprint Molecular cloning and characterization of murine cyclin E
    I Damjanov
    Department of Pathology and Cell Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107
    Biochem Biophys Res Commun 201:994-1000. 1994
    ..In adult tissues, cycE mRNA is detectable in the spleen and to a lesser extent in the testis and brain. These data show that cycE is developmentally regulated and unevenly expressed in fetal and adult mouse tissues...